Associate Professor Judith Trotman is a hematologist trained in Auckland, Sydney, Melbourne and Lyon. She is a clinician researcher with particular expertise in the management of lymphoid malignancies, and Director of the Hematology Clinical Research Unit, at Concord Repatriation General Hospital, Sydney.
Judith and colleagues have built one of the largest clinical research units in Australia collaborating in a broad portfolio of hematology trials. She is a member of the Australasian Leukemia and Lymphoma Group (ALLG) Scientific Advisory Committee and Chair of the Low Grade Lymphoma committee. She is the ALLG Principal Investigator for several national trials and international lymphoma collaborations: with the French (PET in PRIMA, REMARC); Italian (FOLLCOLL); and UK lymphoma cooperative groups, including the RATHL- Response Adapted Therapy in Hodgkin Lymphoma - study delivering PET-adapted therapy to patients with advanced HL. She is a co-author of the international imaging guidelines in staging and response assessment of lymphoma and leads an international collaboration demonstrating the predictive power of both baseline and end-of treatment PET in follicular lymphoma. She is currently trialing a PET-adapted approach in relapsed FL. Beyond lymphoma she leads a study designed to optimize dosing of high dose melphalan in myeloma transplantation. In this modern digital era, she is committed to facilitating cross-center collaboration in trials recruitment across the broad spectrum of rare hematologic malignancies. She is co-inventor of ClinTrial Refer – the not-for-profit, free-to-download App that has increased patient cross-referral across numerous cancer trial portfolios internationally.